F83 D81
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: a) informed consent of parents and/or patient b) patients with a delay in neurological development, or with a suspicion thereof, based on clinical, morphological, biochemical or moleculargenetic evidence, c) patients with an immunodeficiency, or with a suspicion thereof, based on clinical, morphological, biochemical or moleculargenetic evidence, d) asymptomatic probands/mutation carriers, related to a patient with a secured or suspected delay of neurological development and/or immunodeficiency
Exclusion criteria
Exclusion criteria: a) when none of the inclusion criteria meet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prospective inquiry of clinical data for deep/mechanistic phenotyping in an interventional study via Clinical Research Forms (CRFs) and participant questionnaires, to gain a full understanding of disease progression as groundwork for defining clinical endpoints | — |
Secondary
| Measure | Time frame |
|---|---|
| Employment and analysis of Next-Generation-Sequencing to find pathogenic genetic variants with previously unreported disease phenotypes | — |
Countries
Germany
Contacts
Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Köln